A detailed history of Rathbones Group PLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Rathbones Group PLC holds 89,420 shares of IBRX stock, worth $273,625. This represents 0.0% of its overall portfolio holdings.

Number of Shares
89,420
Previous 73,420 21.79%
Holding current value
$273,625
Previous $272,000 16.18%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$2.56 - $6.17 $40,960 - $98,720
16,000 Added 21.79%
89,420 $228,000
Q3 2023

Nov 13, 2023

BUY
$1.29 - $3.1 $94,711 - $227,602
73,420 New
73,420 $124,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.22B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Rathbones Group PLC Portfolio

Follow Rathbones Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Rathbones Group PLC with notifications on news.